SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
-3.86%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$103M
AUM Growth
+$103M
(-17%)
Cap. Flow
+$6.61M
Cap. Flow
% of AUM
6.43%
Top 10 Holdings %
Top 10 Hldgs %
58.07%
Holding
75
New
23
Increased
18
Reduced
24
Closed
9
Top Buys
| 1 |
ANI Pharmaceuticals
ANIP
|
$7.85M |
| 2 |
OPTN
OptiNose
OPTN
|
$1.83M |
| 3 |
Surrozen
SRZN
|
$1.73M |
| 4 |
Edesa Biotech
EDSA
|
$1.68M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
$1.43M |
Top Sells
| 1 |
Ironwood Pharmaceuticals
IRWD
|
$2.87M |
| 2 |
Galapagos
GLPG
|
$2.66M |
| 3 |
Evolus
EOLS
|
$1.56M |
| 4 |
Verastem
VSTM
|
$1.55M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$1.23M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ANI Pharmaceuticals
ANIP
$2.03B
| $13.6M | 13.28% | 48,000 +27,600 | +135% | +$7.85M |
|
|
2
Evolus
EOLS
$494M
| $13.6M | 13.28% | 1,134,574 -130,077 | -10% | -$1.56M |
|
|
OPTN
3
DELISTED
OptiNose
OPTN
| $7.23M | 7.04% | 788,647 +199,990 | +34% | +$1.83M |
|
4
Zevra Therapeutics
ZVRA
$509M
| $4.87M | 4.74% | 650,000 +52,300 | +9% | +$392K |
|
|
5
Verastem
VSTM
$569M
| $3.7M | 3.6% | 613,000 -257,000 | -30% | -$1.55M |
|
6
UroGen Pharma
URGN
$900M
| $3.69M | 3.59% | 333,400 +9,076 | +3% | +$100K |
|
|
7
Surrozen
SRZN
$104M
| $3.33M | 3.24% | 285,782 +148,582 | +108% | +$1.73M |
|
8
Anika Therapeutics
ANIK
$135M
| $3.26M | 3.17% | 206,639 -31,583 | -13% | -$498K |
|
|
9
Enanta Pharmaceuticals
ENTA
$180M
| $3.26M | 3.17% | 590,742 +258,842 | +78% | +$1.43M |
|
10
Aquestive Therapeutics
AQST
$456M
| $3.04M | 2.96% | 200,000 +40,000 | +25% | +$608K |
|
11
Establishment Labs
ESTA
$1.2B
| $3.04M | 2.96% | 74,500 -5,502 | -7% | -$225K |
|
12
Indivior
INDV
$3.03B
| $2.9M | 2.82% | 304,000 -1,000 | -0.3% | -$9.53K |
|
13
Aclaris Therapeutics
ACRS
$209M
| $2.77M | 2.69% | 527,842 -135,563 | -20% | -$710K |
|
14
Day One Biopharmaceuticals
DAWN
$769M
| $2.77M | 2.69% | 348,820 +113,820 | +48% | +$903K |
|
15
Xoma
XOMA
$392M
| $2.59M | 2.52% | 129,813 +4,113 | +3% | +$82K |
|
16
TELA Bio
TELA
$70.5M
| $2.51M | 2.44% | 2,055,225 -297,874 | -13% | -$363K |
|
|
17
Galapagos
GLPG
$2.07B
| $2.36M | 2.3% | 93,968 -106,032 | -53% | -$2.66M |
|
18
Inhibikase Therapeutics
IKT
$134M
| $2M | 1.95% | 914,973 -217,415 | -19% | -$476K |
|
19
Heron Therapeutics
HRTX
$207M
| $1.75M | 1.7% | 796,100 +96,100 | +14% | +$211K |
|
|
20
Edesa Biotech
EDSA
$16.3M
| $1.68M | 1.63% | +687,500 | New | +$1.68M |
|
21
Myomo
MYO
$39.7M
| $1.33M | 1.3% | 276,707 +2,281 | +0.8% | +$11K |
|
22
Keros Therapeutics
KROS
$618M
| $1.02M | 0.99% | +100,000 | New | +$1.02M |
|
23
Vir Biotechnology
VIR
$686M
| $937K | 0.91% | 144,628 -19,478 | -12% | -$126K |
|
24
scPharmaceuticals
SCPH
$295M
| $914K | 0.89% | 347,687 -335,843 | -49% | -$883K |
|
25
Inovio Pharmaceuticals
INO
$126M
| $845K | 0.82% | 518,331 -531,669 | -51% | -$867K |
|